Spots Global Cancer Trial Database for secondary acute myeloid leukemia

Every month we try and update this database with for secondary acute myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	NCT00052520	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo...	therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method	-	Fred Hutchinson Cancer Center
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia	NCT00003868	Leukemia	cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera...	2 Years - 55 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia	NCT00002549	Leukemia	filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera...	15 Years - 60 Years	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02299518	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	NCT00003602	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin mitoxantrone hy...	55 Years -	National Cancer Institute (NCI)
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT01238211	Acute Myeloid L... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Core Binding Fa... Secondary Acute... Therapy-Related...	Cytarabine Dasatinib Daunorubicin Hy... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant	NCT01640301	Recurrent Adult... Recurrent Child... Secondary Acute... Therapy-Related... Donor Hematopoietic C... HLA-A*0201 Posi... Recurrent Acute...	Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... WT1-Sensitized ...	-	Fred Hutchinson Cancer Center
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers	NCT00015951	Leukemia Myelodysplastic...	bevacizumab cytarabine mitoxantrone hy...	18 Years - 120 Years	University of Maryland, Baltimore
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia	NCT00003003	Leukemia	sargramostim mitomycin C mitoxantrone hy...	18 Years - 120 Years	Dartmouth-Hitchcock Medical Center
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission	NCT00070135	Adult Acute Mye... Acute Myeloid L...	filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema...	60 Years - 74 Years	Alliance for Clinical Trials in Oncology
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia	NCT00039117	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Secondary Acute... Untreated Adult...	oblimersen sodi... cytarabine daunorubicin hy... laboratory biom... pharmacological...	60 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia	NCT00003619	Chronic Myelopr... Leukemia Myelodysplastic... Thrombocytopeni...	filgrastim vitamin E busulfan cytarabine etoposide fludarabine pho... isotretinoin topotecan hydro... bone marrow abl... peripheral bloo...	19 Years - 90 Years	National Cancer Institute (NCI)
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia	NCT00357565	Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo...	filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ...	- 3 Years	Masonic Cancer Center, University of Minnesota
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia	NCT03009240	Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult...	Decitabine Laboratory Biom... Pevonedistat Pharmacological...	18 Years -	City of Hope Medical Center
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	NCT02528877	Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo...	Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia	NCT01627041	Acute Myeloid L... Adult Acute Bas... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Alkylating Agen... Secondary Acute...	Cytarabine Daunorubicin Hy... Decitabine Laboratory Biom... Pharmacological...	18 Years - 65 Years	National Cancer Institute (NCI)
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia	NCT00002588	Leukemia	etoposide topotecan hydro...	18 Years -	Case Comprehensive Cancer Center
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia	NCT02381548	Acute Myeloid L... Blast Phase Chr... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Chron... Refractory Acut... Refractory Chro... Secondary Acute... Therapy-Related... Untreated Adult...	Adavosertib Belinostat Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	NCT00093483	Leukemia	filgrastim arsenic trioxid... cytarabine idarubicin	18 Years - 59 Years	Roswell Park Cancer Institute
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia	NCT00602771	Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult...	tipifarnib etoposide	70 Years -	National Cancer Institute (NCI)
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	NCT04146038	Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute...	Azacitidine Decitabine Salsalate Venetoclax	18 Years -	Rutgers, The State University of New Jersey
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia	NCT00008190	Leukemia	aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo...	-	National Cancer Institute (NCI)
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	NCT00528398	Leukemia	cytarabine idarubicin	16 Years - 60 Years	City of Hope Medical Center
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00124644	Leukemia	cytarabine daunorubicin hy... etoposide tipifarnib chemotherapy enzyme inhibito... high-dose chemo...	18 Years - 59 Years	National Cancer Institute (NCI)
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia	NCT04284787	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Azacitidine Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Pembrolizumab Venetoclax	60 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia	NCT00217646	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... Blastic Phase de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Secondary Acute... Secondary Myelo...	Sorafenib Tosyl...	18 Years -	National Cancer Institute (NCI)
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia	NCT00006122	Leukemia	cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy...	61 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01707004	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute...	decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom...	18 Years - 75 Years	University of Wisconsin, Madison
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00112853	Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult...	tipifarnib etoposide	70 Years -	National Cancer Institute (NCI)
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML	NCT00871689	Leukemia	aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra...	- 45 Years	Masonic Cancer Center, University of Minnesota
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT01349972	Acute Myeloid L... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult...	alvocidib daunorubicin hy... mitoxantrone hy... cytarabine	18 Years - 70 Years	National Cancer Institute (NCI)
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia	NCT01839240	Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Secondary Acute... Untreated Adult...	azacitidine cytarabine mitoxantrone hy... laboratory biom...	18 Years -	University of Chicago
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Empirical Versus Preemptive Antifungal Therapy	NCT01288378	Fungal Infectio... Leukemia Myelodysplastic...	caspofungin ace...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00087204	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo...	becatecarin laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT00454480	Leukemia Myelodysplastic...	alemtuzumab arsenic trioxid... azacitidine busulfan clofarabine cytarabine daunorubicin hy... fludarabine pho... gemtuzumab ozog... melphalan tipifarnib DNA methylation... cytogenetic ana... gene expression... mutation analys... diagnostic labo... immunologic tec... allogeneic hema... nonmyeloablativ...	-	National Cancer Institute (NCI)
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia	NCT00002549	Leukemia	filgrastim busulfan cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mesna mitoxantrone hy... allogeneic bone... autologous bone... peripheral bloo... radiation thera...	15 Years - 60 Years	National Cancer Institute (NCI)
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant	NCT02485535	Acute Myeloid L... de Novo Myelody... Myelodysplastic... Secondary Acute... Secondary Myelo...	Laboratory Biom... Selinexor	-	University of Chicago
Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia	NCT01005277	Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Child... Recurrent Child... Secondary Acute...	Laboratory Biom...	-	Children's Oncology Group
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	NCT00112567	Leukemia Myelodysplastic...	fludarabine pho... thiotepa peripheral bloo... radiation thera...	- 20 Years	Fred Hutchinson Cancer Center
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT00119366	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo...	iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom...	16 Years - 50 Years	Fred Hutchinson Cancer Center
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia	NCT02286726	Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Laboratory Biom... Liposome-encaps...	18 Years -	M.D. Anderson Cancer Center
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia	NCT00005866	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine methotrexate allogeneic bone... radiation thera...	16 Years - 55 Years	SWOG Cancer Research Network
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia	NCT00100971	Leukemia	autologous tumo... therapeutic aut... tumor cell-deri...	18 Years -	Boston Medical Center
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission	NCT00045435	Acute Myeloid L... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute...	nonmyeloablativ... fludarabine pho... total-body irra... cyclosporine mycophenolate m... peripheral bloo...	55 Years -	Fred Hutchinson Cancer Center
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies	NCT00356928	Leukemia Myelodysplastic...	Cyclophosphamid... Donor T cells	18 Years - 120 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia	NCT00002926	Leukemia Myelodysplastic...	cytarabine etoposide idarubicin allogeneic bone... peripheral bloo...	16 Years - 60 Years	National Cancer Institute (NCI)
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia	NCT00052299	Leukemia	cytarabine etoposide gemtuzumab ozog... idarubicin mitoxantrone hy...	61 Years - 75 Years	European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia	NCT00003436	Leukemia Myelodysplastic...	amsacrine asparaginase cytarabine daunorubicin hy... etoposide methotrexate mitoxantrone hy... therapeutic hyd... allogeneic bone...	- 15 Years	National Cancer Institute (NCI)
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	NCT02890329	Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo...	Decitabine Ipilimumab	18 Years -	National Cancer Institute (NCI)
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	NCT04269213	Acute Myeloid L... Acute Myeloid L... Secondary Acute... Therapy-Related...	Liposome-encaps...	18 Years - 59 Years	Roswell Park Cancer Institute
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia	NCT00352365	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Secondary Acute... Untreated Adult...	lenalidomide	60 Years -	National Cancer Institute (NCI)
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia	NCT00528398	Leukemia	cytarabine idarubicin	16 Years - 60 Years	City of Hope Medical Center
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia	NCT00703300	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... Untreated Adult...	bortezomib decitabine pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia	NCT01876953	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... Untreated Adult...	cytarabine idarubicin dasatinib laboratory biom...	18 Years -	City of Hope Medical Center
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases	NCT00450983	Graft Versus Ho... Leukemia Myelodysplastic...	muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra...	- 45 Years	Fred Hutchinson Cancer Center
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome	NCT00002547	Leukemia Myelodysplastic...	busulfan cyclophosphamid... cyclosporine cytarabine methotrexate allogeneic bone... syngeneic bone ...	- 60 Years	Barbara Ann Karmanos Cancer Institute
TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia	NCT04518345	Acute Myeloid L... Secondary Acute... Therapy-Related...	Azacitidine Dubermatinib	18 Years -	Ohio State University Comprehensive Cancer Center
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia	NCT04214249	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... Secondary Acute...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Cytarabine Daunorubicin Hy... Echocardiograph... Hematopoietic C... Idarubicin Hydr... Multigated Acqu... Pembrolizumab Punch Biopsy	18 Years - 75 Years	National Cancer Institute (NCI)
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia	NCT00002658	Leukemia Neutropenia	filgrastim amsacrine cyclophosphamid... cytarabine daunorubicin hy... etoposide idarubicin mitoxantrone hy... thioguanine tretinoin allogeneic bone... autologous bone... peripheral bloo... radiation thera...	15 Years -	National Cancer Institute (NCI)
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia	NCT00838240	Leukemia Myelodysplastic...	clofarabine cytarabine idarubicin	18 Years - 60 Years	European Organisation for Research and Treatment of Cancer - EORTC
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations	NCT02323607	Recurrent Adult... Secondary Acute... Therapy-Related... Untreated Adult...	Pacritinib Cytarabine Daunorubicin Hy... Decitabine Laboratory Biom... Pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS	NCT01300572	Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Secondary Acute...	Allogeneic Bone... Allogeneic Hema... Cyclosporine Fludarabine Pho... Indium In 111 A... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Pharmacological... Total-Body Irra... Yttrium Y 90 An...	18 Years -	Fred Hutchinson Cancer Center
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02316964	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	decitabine natural killer ... aldesleukin laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	NCT02044796	Acute Biphenoty... de Novo Myelody... Previously Trea... Recurrent Adult... Untreated Adult... Secondary Acute...	Cladribine Cytarabine Filgrastim Laboratory Biom... Mitoxantrone Hy...	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia	NCT00002912	Leukemia	etoposide mitoxantrone hy... valspodar	- 21 Years	National Cancer Institute (NCI)
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	NCT03150004	Acute Myeloid L... Myelodysplastic...	Cladribine, Cyt... Cladribine and ...	18 Years -	Medical College of Wisconsin

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: